Publicacións nas que colabora con Alberto Cordero Fort (37)

2024

  1. Applicability of the Zwolle score for selection of very high-risk ST-elevation myocardial infarction patients treated with primary angioplasty

    Angiology, Vol. 75, Núm. 2, pp. 175-181

2023

  1. Effect of dapagliflozin on COVID-19 infection and risk of hospitalization

    The Journal of antimicrobial chemotherapy, Vol. 78, Núm. 9, pp. 2335-2342

  2. Remnant cholesterol in patients admitted for acute coronary syndromes

    European journal of preventive cardiology, Vol. 30, Núm. 4, pp. 340-348

  3. The efficacy of intensive lipid-lowering therapies on the reduction of LDLc and of major cardiovascular events

    Journal of Clinical Lipidology, Vol. 17, Núm. 5, pp. 602-611

2022

  1. Clinical and therapeutic characterization of the ischemic cardiopathy in Spain. Importance of cardiac rehabilitation programs

    Medicina Clinica Practica, Vol. 5, Núm. 3

  2. Effect of PCSK9 inhibitors on remnant cholesterol and lipid residual risk: The LIPID-REAL registry

    European Journal of Clinical Investigation, Vol. 52, Núm. 12

  3. Impact of the COVID-19 pandemic in the lipid control of the patients that start PCSK9 inhibitors

    Clinica e Investigacion en Arteriosclerosis, Vol. 34, Núm. 5, pp. 245-252

  4. Mortality and Heart Failure Risk Reductions in Patients Treated With Sacubitril-Valsartan in Clinical Trials

    American journal of therapeutics, Vol. 29, Núm. 5, pp. e572-e575

  5. Sex Differences in Low-Density Lipoprotein Cholesterol Reduction with PCSK9 Inhibitors in Real-world Patients: The LIPID-REAL Registry

    Journal of Cardiovascular Pharmacology, Vol. 79, Núm. 4, pp. 523-529

  6. Should PRECISE-DAPT be included for long-term prognostic stratification of diabetic patients with NSTEACS?

    Acta Diabetologica, Vol. 59, Núm. 2, pp. 163-170

  7. The CNIC-Polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: The NEPTUNO study

    International Journal of Cardiology, Vol. 361, pp. 116-123

2021

  1. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events

    Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169

  2. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

  3. Mortality associated with cardiovascular disease in patients with COVID-19

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 30-38

  4. Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

2020

  1. Early revascularization and long-term mortality in high-risk patients with non–ST-elevation myocardial infarction. The CARDIOCHUS-HUSJ registry

    Revista Espanola de Cardiologia, Vol. 73, Núm. 1, pp. 35-42

  2. Long-term bleeding risk vs. mortality risk in acute coronary syndrome patients according to the 2019 ARC-HBR definition

    Thrombosis Research

2019

  1. Estimated Percentage of Patients With Stable Coronary Heart Disease Candidates for PCSK9 Inhibitors

    Revista Espanola de Cardiologia

  2. Incidence and predictors of stroke in patients discharged with the diagnosis of acute coronary syndrome

    International Journal of Cardiology, Vol. 276, pp. 20-25

2018

  1. Determinants and Prognostic Impact of Heart Failure and Left Ventricular Ejection Fraction in Acute Coronary Syndrome Settings

    Revista Espanola de Cardiologia, Vol. 71, Núm. 10, pp. 820-828